Tarceva Survival Benefit Differentiates Oncologic From Iressa – Genentech

The survival benefit seen in Genentech/OSI's Tarceva non-small cell lung cancer monotherapy trial shows it is a "better product" than AstraZeneca's Iressa, Genentech maintained April 26